Inhouse product
Mounjaro 12.5 mg (tirzepatide) is a medication designed for the treatment of type 2 diabetes in adults. It is administered as a subcutaneous injection and belongs to the drug class known as incretin mimetics1. Mounjaro functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist2.
Dosage and Administration: Mounjaro is available in single-dose, prefilled pens at various strengths, including the 12.5 mg/0.5 mL dosage2. The typical starting dose is 2.5 mg once weekly, which may be adjusted based on the individual’s blood sugar control, up to a maximum of 15 mg once per week2.
Mechanism of Action: The medication works by activating GIP and GLP-1 receptors, which are natural hormones that regulate blood sugar levels. By stimulating these receptors, Mounjaro helps the pancreas produce more insulin when blood sugar levels are high, reduces the amount of sugar produced by the liver, and slows down food passing through the stomach, making you feel full longer1.
Clinical Trials and Approvals: Mounjaro was FDA-approved on May 13, 2022, for improving blood sugar levels in adults with type 2 diabetes when used alongside diet and exercise1. Clinical trials have demonstrated significant weight loss in patients using tirzepatide, with an average of 20.9% body weight reduction over 72 weeks for the 15 mg dose compared to 3.1% for placebo1. However, it’s important to note that while the active ingredient tirzepatide is approved for weight loss under the brand name Zepbound, Mounjaro itself is not approved for weight loss1.
Precautions: Injection Mounjaro is not indicated for use in individuals with type 1 diabetes or for those who have had pancreatitis. It is essential to discuss with a healthcare provider to ensure Mounjaro is appropriate for your specific health condition1.
Login or Registerto submit your questions to seller
No none asked to seller yet